Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
1. Does transplant medicine have a new blood test that is better than creatinine?
— Nephrology Jrnl Club (@NephJC) July 1, 2022
Aye aye ADMIRAL 🫡
Join us as we recap last week's #NephJC chat on this edition of #TenTweetNephJC brought to you by @jamiekwillows and @michaelturk6 pic.twitter.com/gAS70VKG8i